No authorization for the biologic
Biologics are almost always on prior authorization lists, with renewals every 6 to 12 months.
How we prevent it: We track every patient’s authorization and renew before it expires.
Rheumatology billing centers on infusions and injectable biologics, where drug units, administration codes and prior authorizations drive reimbursement.
Upfront or setup fees
Revenue cycle steps managed end to end
Specialties and lab types we bill for
Of your data and systems stay yours
Rheumatology billing centers on infusions and injectable biologics. Infliximab, abatacept, tocilizumab and their biosimilars are expensive, tightly managed by payers and billed with administration codes that depend on the drug and the documented infusion times.
Payers require prior authorization, step therapy, preferred biosimilars and sometimes a specific site of care. Joint injections, aspirations and ultrasound guidance add their own bundling and documentation rules.
We handle rheumatology billing from authorization to payment: confirming the preferred product, securing approval, coding the administration and drug correctly, and appealing denials with the clinical history payers ask for.
Also see our medical coding, denial management, eligibility verification and revenue cycle management services.
Rheumatology claims mix drug administration, drugs, joint procedures and imaging.
| Code | Description | What we watch for |
|---|---|---|
| 96413 | Complex drug administration, IV infusion, up to 1 hour | Used for many biologic infusions such as infliximab, per payer policy. |
| 96365 | Therapeutic IV infusion, initial, up to 1 hour | For infusions that do not meet the complex drug administration criteria. |
| 96372 | Therapeutic injection, subcutaneous or intramuscular | For in-office injections of biologics and corticosteroids. |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Many plans require a biosimilar first; billing the wrong product is a common denial. |
| Q5103 | Injection, infliximab-dyyb, biosimilar, 10 mg | Each biosimilar has its own Q-code; units are per 10 mg. |
| J0129 | Injection, abatacept, 10 mg | IV doses are weight based; units must match the dose given. |
| J3262 | Injection, tocilizumab, 1 mg | Dose and frequency are checked against the approved authorization. |
| 20610 | Arthrocentesis, aspiration or injection, major joint, without ultrasound guidance | Use 20611 when ultrasound guidance is used and documented with images. |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Bill the drug with the joint injection procedure. |
| 77080 | DXA bone density study, axial skeleton | Medicare covers repeat studies at set intervals based on risk. |
Code descriptions are summarized. CPT® is a registered trademark of the American Medical Association. Coverage and payment rules vary by payer and change every year; we code to the current code set and your payers’ policies.
Drug wasteReport discarded drug, or none discarded, on single-dose vial drugs.
Right and left sideIdentify the joint injected; use both for bilateral injections per payer rules.
Significant, separate E/MFor a visit that goes beyond the decision to inject a joint.
Separate structureFor injections into different joints when NCCI pairs the codes.
The denial reasons we see most often in rheumatology billing, with the claim adjustment reason code (CARC) payers usually attach, and what we do so they don't happen again.
Biologics are almost always on prior authorization lists, with renewals every 6 to 12 months.
How we prevent it: We track every patient’s authorization and renew before it expires.
Payers require documented failure of conventional DMARDs before approving a biologic.
How we prevent it: We include prior treatments, dates and outcomes in every authorization and appeal.
Billing the reference product when the plan requires a biosimilar, or omitting the NDC, stops payment.
How we prevent it: We confirm the preferred product and include NDCs on every drug line.
Ultrasound guidance billed separately with 20611, or a visit without modifier 25, is bundled.
How we prevent it: We use the guided injection code and add 25 only when the visit is separately documented.
Units or dosing intervals above the authorization are denied.
How we prevent it: We compare each claim to the approved dose, units and interval before submission.
From the first eligibility check to the final patient payment, one dedicated team handles every step and reports back to you.
We verify coverage, benefits, copays and deductibles before the visit. For rheumatology, that includes biologic authorizations, step therapy documentation and site-of-care rules.
Our coders review documentation and assign CPT, HCPCS and ICD-10-CM codes to the highest supported specificity. Infusion times, drug units and joint procedures are coded from the infusion record and notes.
Every claim is checked against NCCI edits, payer policies and modifier rules before it goes out electronically, so it is paid on the first pass.
We post ERAs and EOBs, compare payments to your contracted rates and flag underpayments for appeal.
Every denial is worked: corrected, appealed or escalated, with root causes fed back to the front end. Biologic denials are appealed with prior treatment history and disease activity scores.
You get clear monthly reports on collections, denials and A/R aging, and patients get easy-to-read statements and answers to billing questions.
Rules that change how rheumatology claims must be coded, documented and submitted.
Biosimilar policies: many plans require a specific biosimilar and deny the reference product.
Site of care: some payers move infusions from hospital outpatient to office or home infusion.
Buy-and-bill versus specialty pharmacy: the drug may be billed by the practice or supplied by a specialty pharmacy.
Imaging guidance: ultrasound-guided joint injections need permanently recorded images and a report.
Send us a sample of your rheumatology denials and A/R. We'll show you where revenue is slipping and how we'd fix it, with no obligation and no upfront fees.